PAP
BNTC icon

Persistent Asset Partners’s Benitec Biopharma BNTC Stock Holding History

Persistent Asset Partners’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$195K Sell
18,307
-2,446
-12% -$28.3K 0.07% 195
2025
Q4 		$280K Buy
+20,753
New +$287K 0.13% 187

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Persistent Asset Partners's BNTC Position: Q1 2026 in Review

Persistent Asset Partners reduced its Benitec Biopharma (BNTC) stake by 12% in Q1 2026, selling an estimated $28.3K and leaving 18,307 shares worth $195K. The position accounts for 0.07% of the portfolio, ranked #195.

Persistent Asset Partners first reported a position in BNTC in Q4 2025 and has held it in 2 quarters since. The position peaked at $280K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Persistent Asset Partners held 18,307 shares of Benitec Biopharma worth $195K as of Q1 2026.
  • Persistent Asset Partners sold 2,446 Benitec Biopharma shares in Q1 2026, an estimated $28.3K.
  • Benitec Biopharma made up 0.07% of Persistent Asset Partners's portfolio in Q1 2026, its #195 holding.
  • Persistent Asset Partners first reported a position in Benitec Biopharma in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Benitec Biopharma position peaked at $280K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.